Vir Biotechnology Inc
VIR - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.91B
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $1.91 Billion |
|---|---|
| Enterprise Value | $1.73 Billion |
| Earnings per Share | $-3.16 |
| Beta | 1.59 |
| Outstanding Shares | 167,719,015 |
Return
| Return on Equity | -25.62% |
|---|---|
| Return on Assets | -20.72% |
| Return on Invested Capital | -24.39% |
Valuation & Multiples
| P/E Ratio | -6.11 |
|---|---|
| PEG | 3.55 |
| Price to Sales | 11.77 |
| Price to Book Ratio | 2.35 |
| Enterprise Value to Revenue | 5.69 |
| Enterprise Value to EBIT | -6.32 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.09 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 4, 2026
EPS Estimate
$-0.75
Consensus analyst estimateRevenue Estimate
$980,000
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 54.13% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.67%▼ 87.53% |
|---|---|
| Total Invested | $12.41M▼ 99.18% |
| Investors Holding | 57▼ 189.00% |
About Vir Biotechnology Inc
327 employees
Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are desi...